全文获取类型
收费全文 | 395篇 |
免费 | 16篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 14篇 |
妇产科学 | 1篇 |
基础医学 | 39篇 |
口腔科学 | 11篇 |
临床医学 | 26篇 |
内科学 | 111篇 |
皮肤病学 | 4篇 |
神经病学 | 21篇 |
特种医学 | 45篇 |
外科学 | 86篇 |
综合类 | 3篇 |
预防医学 | 21篇 |
眼科学 | 5篇 |
药学 | 11篇 |
肿瘤学 | 17篇 |
出版年
2022年 | 2篇 |
2020年 | 2篇 |
2019年 | 2篇 |
2018年 | 2篇 |
2017年 | 8篇 |
2016年 | 3篇 |
2015年 | 4篇 |
2014年 | 10篇 |
2013年 | 11篇 |
2012年 | 7篇 |
2011年 | 9篇 |
2010年 | 15篇 |
2009年 | 7篇 |
2008年 | 17篇 |
2007年 | 15篇 |
2006年 | 10篇 |
2005年 | 22篇 |
2004年 | 20篇 |
2003年 | 8篇 |
2002年 | 5篇 |
2001年 | 8篇 |
2000年 | 6篇 |
1999年 | 10篇 |
1998年 | 14篇 |
1997年 | 14篇 |
1996年 | 21篇 |
1995年 | 15篇 |
1994年 | 15篇 |
1993年 | 15篇 |
1992年 | 6篇 |
1990年 | 5篇 |
1989年 | 8篇 |
1988年 | 12篇 |
1987年 | 10篇 |
1986年 | 14篇 |
1985年 | 10篇 |
1984年 | 7篇 |
1983年 | 6篇 |
1981年 | 5篇 |
1980年 | 6篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1977年 | 4篇 |
1976年 | 3篇 |
1975年 | 2篇 |
1967年 | 3篇 |
1959年 | 2篇 |
1929年 | 1篇 |
1919年 | 1篇 |
1889年 | 1篇 |
排序方式: 共有417条查询结果,搜索用时 15 毫秒
1.
Bone stock preservation is crucial when performing total hip replacement in young patients. The aim is to save good bone stock
for a possible revision procedure. Furthermore, there is an increasing demand from young and active patients to receive a
new joint which allows a normal or nearly normal life style. With this in mind, we began, in 1993, to develop a new femoral
implant. The purpose of this ultra-short stem was a physiologic strain distribution on the proximal femur with a proximal
load transfer from the implant to the femoral bone. Main features were an almost complete absence of the diaphyseal portion
of the stem, a well defined lateral flare with load transfer on the lateral column of the femur, and a very high femoral neck
cut. These innovations resulted in a conservative implant on both the bone stock and the soft tissues. This implant, in the
first years, was recommended only for young and active patients. Over the last thirteen years, this project has undergone
several modifications but the basic principles of the implant have remained the same. In the present review, we present the
rationale, the surgical technique and the clinical and experimental results so far obtained with this implant. 相似文献
2.
3.
4.
5.
HLA-A2-restricted CD8+-cytotoxic-T-cell responses to novel epitopes in Mycobacterium tuberculosis superoxide dismutase, alanine dehydrogenase, and glutamine synthetase 总被引:4,自引:0,他引:4
下载免费PDF全文
![点击此处可从《Infection and immunity》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Dong Y Demaria S Sun X Santori FR Jesdale BM De Groot AS Rom WN Bushkin Y 《Infection and immunity》2004,72(4):2412-2415
Major histocompatibility complex class I-restricted CD8(+) cytotoxic T lymphocytes (CTL) are implicated in protective Th1 immunity to Mycobacterium tuberculosis infection. We report the identification of three novel HLA-A*0201-restricted CTL epitopes within mycobacterial superoxide dismutase (SodA), L-alanine dehydrogenase (AlaDH), and L-glutamine synthetase (GlnS) proteins. 相似文献
6.
Alport syndrome: HLA association and kidney graft outcome. 总被引:1,自引:0,他引:1
S Barocci S Fiordoro G Santori U Valente M Mossa P Antonelli G B Ferrara G Cannella A Nocera 《European journal of immunogenetics》2004,31(3):115-119
Alport syndrome (AS) is a genetic disease of type IV collagen involving non-homogeneous patterns of inheritance characterized clinically by the presence of progressive haematuric nephritis leading to end-stage renal disease (ESRD), hearing loss and/or ophthalmologic abnormalities. The aim of this study was to investigate, in a cohort of AS patients who had undergone a kidney graft (KG) or who were still on a waiting list for a KG, (a) whether there is a correlation between AS and HLA antigen expression, and (b) long-term graft outcome in transplant patients. The AS cohort was represented by 34 ESRD patients, of whom 25 received a KG and the remaining nine were still on a waiting list. AS transplant patients represented 2.78% of 899 first KGs performed at our centre (Transplantation Department at S. Martino Hospital, Genoa) between 1983 and 2002. Grafts were procured from cadaveric donors in 18 cases and from living, related donors in seven cases. All AS transplant patients had a post-transplant follow-up period of at least 12 months. Results showed that: (i) the frequency of the HLA-DRB1*16 antigen was significantly increased in the whole AS cohort as compared to 128 healthy subjects (HS) (corrected P-value 0.0026; relative risk 7.20) as well as to 232 non-AS ESRD patients on a waiting list for KG (corrected P-values 0.0156; relative risk 4.67); (ii) 5- and 10-year graft survivals in the AS transplant patients were 80 and 73%, respectively, and did not differ from those of a control group represented by 25 non-AS KG recipients matched for sex, age, number of HLA mismatches and immunosuppressive treatment. Increased frequency of HLA-DRB1*16 in AS patients may reflect a linkage disequilibrium with genes coding for collagen synthesis. 相似文献
7.
Standard radiographic projections have poor diagnostic ability in detecting early degenerative changes of the hip. Comparison of arthroscopic and radiographic findings is the best method to assess the accuracy of conventional radiography. This study reviewed the records and radiographs of 234 hip arthroscopies. One hundred eighty-six of the patients had normal preoperative radiographs; of these, 60 (32.2%) had evidence of osteoarthritis at arthroscopy. The extent and location of the chondral damage were studied, and both of these parameters were correlated to the radiographic appearance of osteoarthritis. Hips with normal radiographs but arthroscopic osteoarthritis were found to have less damage compared with the radiographically osteoarthritic hip. Hips with normal radiographs also were more likely to have only one side (60%) of the joint damaged, either the acetabulum or femoral head. Conversely, when osteoarthritis was evident radiographically, both sides of the joint were usually involved (75.7%). These patients are often young (average age: 36 years), and women are more likely to be affected than men (71% versus 29%). 相似文献
8.
The high exposure due to radon and daughter products found in many Italian radioactive spas, suggested a research program designed to assess the lung and skeletal doses accumulated by the subjects working in those spas. The assessment of such doses will permit the evaluation of the significance of a follow-up of the exposed subjects with epidemiological studies. In this paper some preliminary results will be discussed, mainly related to the estimation of the210Po skeletal doses in a few subjects. The210Pb210Po skeletal burdens in the subjects have been evaluated on the basis of their210Pb210Po urinary excretion collected at various intervals during a period of 1 year. The experimental results on the most exposed subjects have shown skeletal doses of the order of 20–40 rem/year and lung exposures higher than 100 WLM (Working Level Month). 相似文献
9.
Deeg HJ; Storb R; Thomas ED; Flournoy N; Kennedy MS; Banaji M; Appelbaum FR; Bensinger WI; Buckner CD; Clift RA 《Blood》1985,65(6):1325-1334
Seventy-five patients, 13 to 49 years of age, with acute nonlymphoblastic leukemia in first remission were treated with cyclophosphamide, fractionated total body irradiation, and marrow transplantation from an HLA-identical sibling and randomized to receive either cyclosporine (CSP) (n = 36) or methotrexate (MTX) (n = 39) as prophylaxis for graft-v-host disease (GVHD). All patients engrafted, and 22 who were given CSP and 21 who were given MTX, are alive at 20 to 47 (median, 35) months (P = .5). Engraftment as assessed by granulocyte recovery (P less than .0005) and platelet transfusion requirement (P = .01) was faster in patients on CSP. Twelve patients (33%) on CSP and 22 (56%) on MTX developed acute GVHD of grades II through IV (P = .07) and 15 of 30 on CSP and 14 of 32 on MTX that were at risk developed chronic GVHD. The most frequent causes of death were interstitial pneumonitis and marrow relapse of leukemia, which occurred with similar frequency in both groups. Beneficial effects observed in patients on CSP included less severe mucositis and shorter duration of hospitalization; adverse effects included renal function impairment and hypertension. These data confirm that CSP is a useful immunosuppressant in patients undergoing marrow transplantation but fail to show a significant improvement in survival as compared with the standard regimen of MTX. 相似文献
10.
Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia 总被引:1,自引:1,他引:1
Robinson N; Sanders JE; Benyunes MC; Beach K; Lindgren C; Thompson JA; Appelbaum FR; Fefer A 《Blood》1996,87(4):1249-1254
Allogeneic bone marrow transplantation (BMT) for advanced acute leukemia is associated with a high risk of relapse. It is postulated that interleukin-2 (IL-2) administered after BMT might induce or amplify a graft-versus-leukemia effect and thereby reduce the relapse rate. To identify an IL-2 regimen for testing this hypothesis, a phase I trial of IL-2 (Roche) was performed in children in complete remission (CR) without active graft-versus-host disease (GVHD) off immunosuppressive agents after unmodified allogeneic matched-sibling BMT for acute leukemia beyond first remission. Beginning a median of 68 days after BMT, 17 patients received escalating doses of induction IL-2 (0.9, 3.0, or 6.0 x 10(6) IU/m2/d representing levels I, II, and III) for 5 days by continuous intravenous infusion (CIV). After 6 days of rest, they received maintenance IL-2 (0.9 x 10(6) IU/m2/d) for 10 days by CIV infusion. Levels I and II were well-tolerated, but, of 6 patients at level III, 1 developed pulmonary infiltrates, 1 developed hypotension (both resolved), and 1 died of bacterial sepsis and acute respiratory distress syndrome. Grade II acute GVHD developed in 1 patient at level I and 1 at level III. The maximum tolerated dose of induction IL-2 was level II. IL-2 induced lymphocytosis, with an increase in CD56+ and CD8+ cells. Ten patients remain in CR at 5+ to 67+ months. Thus, a regimen of IL-2 has been identified that did not induce a high incidence of acute GVHD when administered to children after unmodified allogeneic BMT. Its clinical activity will be assessed in a phase II trial. 相似文献